Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.

about

Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages

P2860

Q58104261-F034858A-2053-48C9-A67F-7B5A7C272BB5

P2860

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.

Item

http://www.wikidata.org/entity/Q36178775

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Systems assessment of intercal ...... ne in advanced NSCLC patients.

@en

type

Item

label

Systems assessment of intercal ...... ne in advanced NSCLC patients.

@en

prefLabel

Systems assessment of intercal ...... ne in advanced NSCLC patients.

@en

P1476

Systems assessment of intercal ...... ne in advanced NSCLC patients.

@en

P2093

Bangwei Cao

http://www.w3.org/2001/XMLSchema#string

Han Yan

http://www.w3.org/2001/XMLSchema#string

Hongchao Zhen

http://www.w3.org/2001/XMLSchema#string

Qin Li

http://www.w3.org/2001/XMLSchema#string

Wei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Operating characteristics of a rank correlation test for publication bias

Cancer statistics, 2014

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Beta blockade during and after myocardial infarction: an overview of the randomized trials.

P2888

srep15355

P304

15355

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1038/SREP15355

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283873015

http://www.w3.org/2001/XMLSchema#string

P698

26481697

http://www.w3.org/2001/XMLSchema#string

P932

4611484

http://www.w3.org/2001/XMLSchema#string

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.

about

P2860

P2860

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P5875

P698

P932